“The existing situation has uncovered some structural weaknesses from the EU’s medicines provide chain in addition to a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She advised that provide chain problems be resolved within an EU pharmaceutica